GlaxoSmithKline registers phase 3 trial of mRNA seasonal influenza vaccine
This study was first posted on ClinicalTrials.gov on October 1, 2026. The trial plans to enroll 3000 participants and aims to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine in adults 18-64 years of age.
Primary source
ClinicalTrials.gov registry record, October 1, 2026
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
Read the source: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation